Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anifrolumab Impact on Vaccine-Emergent Immunity in SLE
NCT04726553Phase 1Unknown
- Sponsor
- Oklahoma Medical Research Foundation
- Start
- Jan 2021
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in systemic lupus erythematosus (SLE) comparing Anifrolumab plus Standard of Care with Standard of Care (2 arms). Primary endpoint: Change in immune response to quadrivalent flu vaccine. Status: unknown.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04726553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04726553.